Mode
Text Size
Log in / Sign up
N/A N=153 Supportive Care

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

Amyotrophic Lateral Sclerosis

Enrolled (actual)
153
Serious AEs
27.5%
Results posted
Jul 2019
Primary outcome: Primary: Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment. — 0; 23; 35 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Early NIPPV (Device); Standard NIPPV (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Edward Kasaraskis
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.
0; 23; 35

Summary

The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.

Eligibility Criteria

Inclusion Criteria

  • Willing and able to give informed consent.
  • If women of childbearing age, must be non-lactating and surgically sterile or using an effective method of birth control (double-barrier or oral contraception) and have a negative pregnancy test.
  • Minorities: All races and ethnic backgrounds.
  • Disease inclusion: Clinically possible/definite/probable, or laboratory supported probable, sporadic or familial ALS according to the revised Escorial criteria.
  • Onset of progressive weakness within 60 months prior to study.
  • Willing to return for visits as scheduled and adhere to protocol requirements.

FVC Criteria

  • NIPPV Arm: Best-sitting FVC between 50% and 95% of predicted normal.
  • Nutrition Arm: Best-sitting FVC >50% of predicted normal.

Exclusion Criteria

  • Untreated or unstable hyper or hypothyroidism, untreated or unstable asthma, unstable angina, advanced liver or renal disease, advanced cancer, untreated diabetes or chronic obstructive pulmonary disease (COPD).
  • Diagnosis of other motor neuron or other neurological disorder that mimics ALS.
  • Diagnosis of other neurodegenerative disease (i.e., Parkinson's disease, Alzheimer's disease, etc.)
  • Inflammatory bowel disease or malabsorption syndrome.
  • Use of NIPPV, mechanical ventilation, or tracheostomy at the time of consent.
  • Inability to adhere to study visit schedule or lack of reliable caretaker if participant requires one.
  • Pregnant or lactating woman.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00116558). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search